Can the BPC-157 ‘Wolverine’ Peptide Really Help With Pain and Recovery?

A new study shows a 33-fold increase in new BPC-157 users in recent years. Compassionate Eye Foundation/Jonathan Bielaski/DigitalVision/Getty Images Proponents of BPC-157, the “Wolverine” peptide, tout injury recovery and pain relief despite limited human evidence to establish safety and effectiveness. Until the potential for adverse reactions is better understood, particularly with long-term use, experts advise against unapproved peptides. There are other proven treatment options for pain relief and recovery recommended by medical professionals. Wellness seekers are increasingly turning to BPC-157, the wildly popular “Wolverine” peptide for injury recovery and pain relief, despite scant human evidence. The Food and Drug Administration (FDA) advisory panel voted in July to ease restrictions on it and several other peptides, recommending the injectable substances be made eligible for pharmacy compounding. But before restrictions were eased, preliminary research suggests a rise in the use of the Wolverine peptide in recent years. A September 2026 preprint analyzed more than 15 million medical records and identified 1,039 people with documented BPC-157 use. The researchers found a ro…

≈